A novel, polymer-coated oncolytic measles virus overcomes immune suppression and induces robust antitumor activity

Kaname Nosaki, Katsuyuki Hamada, Yuto Takashima, Miyako Sagara, Yumiko Matsumura, Shohei Miyamoto, Yasuki Hijikata, Toshihiko Okazaki, Yoichi Nakanishi, Kenzaburo Tani

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Although various therapies are available to treat cancers, including surgery, chemotherapy, and radiotherapy, cancer has been the leading cause of death in Japan for the last 30 years, and new therapeutic modalities are urgently needed. As a new modality, there has recently been great interest in oncolytic virotherapy, with measles virus being a candidate virus expected to show strong antitumor effects. The efficacy of virotherapy, however, was strongly limited by the host immune response in previous clinical trials. To enhance and prolong the antitumor activity of virotherapy, we combined the use of two newly developed tools: the genetically engineered measles virus (MV-NPL) and the multilayer virus-coating method of layer-by-layer deposition of ionic polymers. We compared the oncolytic effects of this polymer-coated MV-NPL with the naked MV-NPL, both in vitro and in vivo. In the presence of anti-MV neutralizing antibodies, the polymer-coated virus showed more enhanced oncolytic activity than did the naked MV-NPL in vitro. We also examined antitumor activities in virus-treated mice. Complement-dependent cytotoxicity and antitumor activities were higher in mice treated with polymer-coated MV-NPL than in mice treated with the naked virus. This novel, polymer-coated MV-NPL is promising for clinical cancer therapy in the future.

Original languageEnglish
Article number16022
Number of pages1
JournalMolecular Therapy - Oncolytics
Volume3
DOIs
Publication statusPublished - Nov 2 2016

Fingerprint

Oncolytic Viruses
Measles virus
Polymers
Viruses
Oncolytic Virotherapy
Neoplasms
Neutralizing Antibodies
Cause of Death
Japan
Radiotherapy
Therapeutics
Clinical Trials
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Oncology
  • Cancer Research
  • Pharmacology (medical)

Cite this

A novel, polymer-coated oncolytic measles virus overcomes immune suppression and induces robust antitumor activity. / Nosaki, Kaname; Hamada, Katsuyuki; Takashima, Yuto; Sagara, Miyako; Matsumura, Yumiko; Miyamoto, Shohei; Hijikata, Yasuki; Okazaki, Toshihiko; Nakanishi, Yoichi; Tani, Kenzaburo.

In: Molecular Therapy - Oncolytics, Vol. 3, 16022, 02.11.2016.

Research output: Contribution to journalArticle

Nosaki, K, Hamada, K, Takashima, Y, Sagara, M, Matsumura, Y, Miyamoto, S, Hijikata, Y, Okazaki, T, Nakanishi, Y & Tani, K 2016, 'A novel, polymer-coated oncolytic measles virus overcomes immune suppression and induces robust antitumor activity', Molecular Therapy - Oncolytics, vol. 3, 16022. https://doi.org/10.1038/mto.2016.22
Nosaki, Kaname ; Hamada, Katsuyuki ; Takashima, Yuto ; Sagara, Miyako ; Matsumura, Yumiko ; Miyamoto, Shohei ; Hijikata, Yasuki ; Okazaki, Toshihiko ; Nakanishi, Yoichi ; Tani, Kenzaburo. / A novel, polymer-coated oncolytic measles virus overcomes immune suppression and induces robust antitumor activity. In: Molecular Therapy - Oncolytics. 2016 ; Vol. 3.
@article{3c626fcd582146179b8b739b9f3b8985,
title = "A novel, polymer-coated oncolytic measles virus overcomes immune suppression and induces robust antitumor activity",
abstract = "Although various therapies are available to treat cancers, including surgery, chemotherapy, and radiotherapy, cancer has been the leading cause of death in Japan for the last 30 years, and new therapeutic modalities are urgently needed. As a new modality, there has recently been great interest in oncolytic virotherapy, with measles virus being a candidate virus expected to show strong antitumor effects. The efficacy of virotherapy, however, was strongly limited by the host immune response in previous clinical trials. To enhance and prolong the antitumor activity of virotherapy, we combined the use of two newly developed tools: the genetically engineered measles virus (MV-NPL) and the multilayer virus-coating method of layer-by-layer deposition of ionic polymers. We compared the oncolytic effects of this polymer-coated MV-NPL with the naked MV-NPL, both in vitro and in vivo. In the presence of anti-MV neutralizing antibodies, the polymer-coated virus showed more enhanced oncolytic activity than did the naked MV-NPL in vitro. We also examined antitumor activities in virus-treated mice. Complement-dependent cytotoxicity and antitumor activities were higher in mice treated with polymer-coated MV-NPL than in mice treated with the naked virus. This novel, polymer-coated MV-NPL is promising for clinical cancer therapy in the future.",
author = "Kaname Nosaki and Katsuyuki Hamada and Yuto Takashima and Miyako Sagara and Yumiko Matsumura and Shohei Miyamoto and Yasuki Hijikata and Toshihiko Okazaki and Yoichi Nakanishi and Kenzaburo Tani",
year = "2016",
month = "11",
day = "2",
doi = "10.1038/mto.2016.22",
language = "English",
volume = "3",
journal = "Molecular Therapy - Oncolytics",
issn = "2372-7705",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - A novel, polymer-coated oncolytic measles virus overcomes immune suppression and induces robust antitumor activity

AU - Nosaki, Kaname

AU - Hamada, Katsuyuki

AU - Takashima, Yuto

AU - Sagara, Miyako

AU - Matsumura, Yumiko

AU - Miyamoto, Shohei

AU - Hijikata, Yasuki

AU - Okazaki, Toshihiko

AU - Nakanishi, Yoichi

AU - Tani, Kenzaburo

PY - 2016/11/2

Y1 - 2016/11/2

N2 - Although various therapies are available to treat cancers, including surgery, chemotherapy, and radiotherapy, cancer has been the leading cause of death in Japan for the last 30 years, and new therapeutic modalities are urgently needed. As a new modality, there has recently been great interest in oncolytic virotherapy, with measles virus being a candidate virus expected to show strong antitumor effects. The efficacy of virotherapy, however, was strongly limited by the host immune response in previous clinical trials. To enhance and prolong the antitumor activity of virotherapy, we combined the use of two newly developed tools: the genetically engineered measles virus (MV-NPL) and the multilayer virus-coating method of layer-by-layer deposition of ionic polymers. We compared the oncolytic effects of this polymer-coated MV-NPL with the naked MV-NPL, both in vitro and in vivo. In the presence of anti-MV neutralizing antibodies, the polymer-coated virus showed more enhanced oncolytic activity than did the naked MV-NPL in vitro. We also examined antitumor activities in virus-treated mice. Complement-dependent cytotoxicity and antitumor activities were higher in mice treated with polymer-coated MV-NPL than in mice treated with the naked virus. This novel, polymer-coated MV-NPL is promising for clinical cancer therapy in the future.

AB - Although various therapies are available to treat cancers, including surgery, chemotherapy, and radiotherapy, cancer has been the leading cause of death in Japan for the last 30 years, and new therapeutic modalities are urgently needed. As a new modality, there has recently been great interest in oncolytic virotherapy, with measles virus being a candidate virus expected to show strong antitumor effects. The efficacy of virotherapy, however, was strongly limited by the host immune response in previous clinical trials. To enhance and prolong the antitumor activity of virotherapy, we combined the use of two newly developed tools: the genetically engineered measles virus (MV-NPL) and the multilayer virus-coating method of layer-by-layer deposition of ionic polymers. We compared the oncolytic effects of this polymer-coated MV-NPL with the naked MV-NPL, both in vitro and in vivo. In the presence of anti-MV neutralizing antibodies, the polymer-coated virus showed more enhanced oncolytic activity than did the naked MV-NPL in vitro. We also examined antitumor activities in virus-treated mice. Complement-dependent cytotoxicity and antitumor activities were higher in mice treated with polymer-coated MV-NPL than in mice treated with the naked virus. This novel, polymer-coated MV-NPL is promising for clinical cancer therapy in the future.

UR - http://www.scopus.com/inward/record.url?scp=84994246925&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994246925&partnerID=8YFLogxK

U2 - 10.1038/mto.2016.22

DO - 10.1038/mto.2016.22

M3 - Article

AN - SCOPUS:84994246925

VL - 3

JO - Molecular Therapy - Oncolytics

JF - Molecular Therapy - Oncolytics

SN - 2372-7705

M1 - 16022

ER -